These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer. Miceli C; Tejada A; Castaneda A; Mistry SJ Cancer Gene Ther; 2013 May; 20(5):298-307. PubMed ID: 23618950 [TBL] [Abstract][Full Text] [Related]
43. Inhibition of Fas-mediated apoptosis in mouse insulinoma betaTC-3 cells via an anti-Fas ribozyme. Klein D; Ricordi C; Pugliese A; Pastori RL Hum Gene Ther; 2000 May; 11(7):1033-45. PubMed ID: 10811232 [TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Nishikawa R; Sugiyama T; Narita Y; Furnari F; Cavenee WK; Matsutani M Brain Tumor Pathol; 2004; 21(2):53-6. PubMed ID: 15700833 [TBL] [Abstract][Full Text] [Related]
45. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878 [TBL] [Abstract][Full Text] [Related]
46. Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Saydam O; Glauser DL; Heid I; Turkeri G; Hilbe M; Jacobs AH; Ackermann M; Fraefel C Mol Ther; 2005 Nov; 12(5):803-12. PubMed ID: 16112910 [TBL] [Abstract][Full Text] [Related]
47. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: screening for effective target sites. Kobayashi H; Takemura Y; Wang FS; Oka T; Ohnuma T Int J Cancer; 1999 Jun; 81(6):944-50. PubMed ID: 10362143 [TBL] [Abstract][Full Text] [Related]
48. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447 [TBL] [Abstract][Full Text] [Related]
50. Characterization in vitro and in vivo of hammerhead ribozymes directed against murine tumor necrosis factoralpha. MacKay SL; Tannahill CL; Auffenberg T; Ksontini R; Copeland EM; Moldawer LL Biochem Biophys Res Commun; 1999 Jul; 260(2):390-7. PubMed ID: 10403780 [TBL] [Abstract][Full Text] [Related]
51. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Shore SK; Nabissa PM; Reddy EP Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522 [TBL] [Abstract][Full Text] [Related]
52. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. Gervaix A; Li X; Kraus G; Wong-Staal F J Virol; 1997 Apr; 71(4):3048-53. PubMed ID: 9060665 [TBL] [Abstract][Full Text] [Related]
53. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding. Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131 [TBL] [Abstract][Full Text] [Related]
54. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells. Hayashidani Y; Hiyama E; Murakami Y; Sueda T Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061 [TBL] [Abstract][Full Text] [Related]
55. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294 [TBL] [Abstract][Full Text] [Related]
56. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Bai J; Gorantla S; Banda N; Cagnon L; Rossi J; Akkina R Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940 [TBL] [Abstract][Full Text] [Related]
57. Ribozyme as an approach for growth suppression of human pancreatic cancer. Kijima H; Scanlon KJ Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615 [TBL] [Abstract][Full Text] [Related]
58. Inhibition of tissue factor gene induction and activity using a hairpin ribozyme. Cavusoglu E; Chen I; Rappaport J; Marmur JD Circulation; 2002 May; 105(19):2282-7. PubMed ID: 12010911 [TBL] [Abstract][Full Text] [Related]
59. Ribozyme mediated degradation of beta-amyloid peptide precursor mRNA in COS-7 cells. Denman RB; Smedman M; Ju W; Rubenstein R; Potempska A; Miller DL Nucleic Acids Res; 1994 Jun; 22(12):2375-82. PubMed ID: 8036167 [TBL] [Abstract][Full Text] [Related]
60. Specific gene suppression by engineered ribozymes in monkey cells. Cameron FH; Jennings PA Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9139-43. PubMed ID: 2556702 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]